Skip to content

Cryopreserved Hair Follicles for Disease and Cell Replacement

Characterization of Cryopreserved Plucked Hair Follicles and Generation of Functional Cell Lines for Disease Modeling and Cell Replacement Therapies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06764719
Enrollment
100
Registered
2025-01-08
Start date
2025-01-06
Completion date
2026-03-31
Last updated
2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Injury Traumatic, Sport Injury

Keywords

Hair follicles, stem cells, pluripotent, cell differentiation

Brief summary

To explore the application of cells expanded from plucked hair follicles after collection, transport, and cryopreservation, in disease modeling and cell-based therapies.

Detailed description

Hair Follicles collected and transported in Acorn's proprietary transport media can serve has therapeutic starting materials for future cell-based therapeutics. This study is to characterize primary cell outgrowth, functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s) as well as evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s).

Interventions

None listed

Sponsors

Acorn Biolabs Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Gender: Male or Female. * Age: ≥18 and ≤80 years. * Language proficiency: Able to read and understand English. * Informed consent: Willing to provide written, informed consent to participate in all study activities.

Exclusion criteria

* Scalp/Hair Disorders: Subjects diagnosed with active scalp infections or inflammatory skin conditions. * Systemic Conditions: Subjects with chronic illnesses, such as autoimmune diseases or diabetes, that may impact scalp health or wound healing. * Medications: Subjects on immunosuppressants, steroids, or other medications associated with hair loss.

Design outcomes

Primary

MeasureTime frameDescription
Characterize primary cellular outgrowth(s)30 days10 hair follicles will be placed in a tissue culture plate per participants. Over the course of 30 days, the outgrowth percentage (the number of outgrowths present out of 10 will be monitored and the confluency (percent of cells present in relation to surface area) will be noted for each participant.
Evaluate functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s)21 days1 million keratinocytes will be taken for reprogramming for each participant. The number of iPS colonies observed on day 21 will be noted, resulting in a reprogramming efficiency score.
Evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s)30 daysiPS cell lines which have been confirmed to be pluripotent will be differentiated into pancreatic progenitor cells and hematopoietic stem cells. The cells will be analyzed using FLOW cytometry and the percentage of double positive cells will be noted for each participant. This will be repeated for multiple pathways such as the hematopoietic and endothelial lineage(s).

Countries

Canada

Contacts

Primary ContactDrew Taylor, MSc, PhD
info@acorn.me226-929-8476

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026